Screening for trisomies 21 and 18 with maternal serum placental isoferritin p43 component

Citation
C. Moroz et al., Screening for trisomies 21 and 18 with maternal serum placental isoferritin p43 component, PRENAT DIAG, 20(5), 2000, pp. 395-399
Citations number
27
Categorie Soggetti
Reproductive Medicine","Medical Research Diagnosis & Treatment
Journal title
PRENATAL DIAGNOSIS
ISSN journal
01973851 → ACNP
Volume
20
Issue
5
Year of publication
2000
Pages
395 - 399
Database
ISI
SICI code
0197-3851(200005)20:5<395:SFT2A1>2.0.ZU;2-0
Abstract
A component of placental isoferritin, p43, is an immune-regulatory protein associated with suppression of the immune system. Maternal serum p43 levels increase throughout pregnancy and low serum levels have been associated wi th various pathological pregnancies, particularly those with a defect of pl acentation. We measured maternal serum p43 retrospectively in banked sample s from 42 Down syndrome, 20 Edwards' syndrome and 281 unaffected pregnancie s to assess its screening potential in both the first and second trimesters . The median maternal serum p43 level in Down syndrome was 1.58 times highe r than that in the unaffected pregnancies (p = 0.01, two-tail). The median level was slightly, but not significantly, reduced in Edwards' syndrome. St atistical modelling, including parameters for alpha-fetoprotein, free beta- human chorionic gonadotrophin, and unconjugated oestriol suggested that it might have a role in Down syndrome screening when combined with two or thre e of these markers. Larger scale studies are now needed. Copyright (C) 2000 John Wiley & Sons, Ltd.